INCY - インサイト (Incyte Corporation) インサイト

 INCYのチャート


 INCYの企業情報

symbol INCY
会社名 Incyte Corporation (インサイト)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Commercial Physical_Biological Resarch  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 インサイト(Incyte Corporation)はバイオ医薬品会社であり、治療薬の発見・開発・商品化を主として行う。同社のポートフォリオには、前臨床開発から後期開発までの各段階の化合物、JAKAFI(ルクソリチニブ)およびICLUSIG(ポナチニブ)などの商品化された製品が含まれる。JAKAFI(ルクソリチニブ)は、中間または高リスクの骨髄線維症(MF)を有する患者の治療およびヒドロキシ尿素に不十分な応答または不耐性である真性赤血球増加症(PV)患者の治療に適応される。ICLUSIGの主な標的は、慢性骨髄性白血病およびフィラデルフィア-染色体陽性急性リンパ芽球性白血病で発現される異常なチロシンキナーゼであるB細胞受容体-ABLである。同社はまた、選択的ヤヌス関連キナーゼ1(JAK1)阻害剤のポートフォリオを有している。   インサイトは米国のバイオ医薬品企業。腫瘍学や炎症用に小分子薬剤の開発、商品化を中心に事業を展開。市販品として中間・高リスク骨髄線維症患者の治療薬、JAKAFI(ruxolitinib)を提供。また開発中の薬剤に真性多血症治療薬ruxolitinib、膵臓癌治療薬ruxolitinib、高度な悪性疾患治療薬ruxolitinibなどがある。   Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.
本社所在地 1801 Augustine Cut-Off Wilmington DE 19803 USA
代表者氏名 Herve Hoppenot Herve Hoppenot
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 302-498-6700
設立年月日 33329
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 1208人
url www.incyte.com
nasdaq_url https://www.nasdaq.com/symbol/incy
adr_tso
EBITDA EBITDA(百万ドル) -42.51400
終値(lastsale) 64.17
時価総額(marketcap) 13641094902.33
時価総額 時価総額(百万ドル) 1442.87
売上高 売上高(百万ドル) 1729.488
企業価値(EV) 企業価値(EV)(百万ドル) 12869.058
当期純利益 当期純利益(百万ドル) -102.32100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Incyte Corporation revenues increased 27% to $903.8M. Net income totaled $11.3M vs. loss of $199.6M. Revenues reflect Product revenues net increase of 26% to $700M Product royalty revenues increase of 62% to $103.7M Milestone revenues increase of 11% to $100M. Net Income reflects Other Research and development decrease of 18% to $445M (expense).

 INCYのテクニカル分析


 INCYのニュース

   National Comprehensive Cancer Network® Adds Monjuvi® (tafasitamab-cxix) to its Clinical Practice Guidelines in Oncology for B-cell Lymphomas  2020/08/18 20:02:00 Business Wire
PLANEGG, Germany & MUNICH & WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--National Comprehensive Cancer Network Adds Monjuvi® (tafasitamab-cxix) to its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
   NIH to test remdesivir with Merck KGaA's interferon therapy as a COVID-19 treatment  2020/08/07 13:11:00 Yahoo Finance
The National Institutes of Health said it will conduct a randomized, controlled clinical trial testing a combination of Gilead Sciences Inc.'s remdesivir with Merck KGaA's interferon beta-1a as a treatment for COVID-19 patients. The study plans to enroll 1,000 people who have been hospitalized because of a COVID-19 infection. The federal agency said it expects to have preliminary results in the fall. Since the Food and Drug Administration granted an emergency use authorization to remdesivir in May, several clinical trials have been initiated that aim to pair the investigational therapy with other drugs to see if the combination can better treat severely ill COVID-19 patients. This includes another NIH trial pairing remdesivir with Eli Lilly & Co. and Incyte Corp. 's Olumiant. Roche Holding AG has also said it will test its rheumatoid arthritis drug in combination with remdesivir.
   Incyte earnings beat estimates - Delaware Business Now  2020/08/04 16:42:21 Delaware Business Now
Incyte Corp. reported strong second-quarter earnings, while posting a loss for the first half, due to upfront costs related to an agreement with a German pharma company. Incyte is based near Wilmington. “We continue to execute successfully across all aspects our business,” stated Hervé Hoppenot, CEO of Incyte. For the first half, Incyte recorded an […]
   Incyte Reports 2020 Second Quarter Financial Results and Provides Updates on Key Clinical Programs  2020/08/04 11:00:00 Business Wire
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #earnings--Incyte Reports 2020 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
   The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings  2020/08/02 15:08:50 Benzinga
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts. COVID-19 news flow continued to pour in, with big pharma tie-ups flaunting positive tidings. In the biggest ever coronavirus funding deal, the Sanofi SA (NASDAQ: SNY ) GlaxoSmithKline plc (NYSE: GSK ) won a joint $2.1 billion U.S. federal funding award. Here're the key catalysts for the unfolding week: Conferences 72nd National Hemophilia Foundation's Annual Bleeding Disorders Meeting 2020 (virtual meeting): Aug. 1-8 PDUFA Dates FDA is scheduled to rule on DBV TECHNOLOGIE/S' ADR (NASDAQ: DBVT ) Viaskin peanut allergy patch Wednesday. However, cancellation of the Adcom meeting scheduled May 15 has poured cold water on the prospects of an approval coming through. Trevena Inc (NASDAQ: TRVN ) has a tryst with the FDA Friday, with respect to the NDA for its pain drug oleceridine, which was once rejected by the agency on the premise of inadequacy of clinical data.
   Incyte, MorphoSys Application for Lymphoma Drug Validated  2020/05/21 12:35:00 Zacks Investment Research
Incyte (INCY) and partner MorphoSys' application for tafasitamab gets validation by EMA.
   Resumen: Incyte y MorphoSys anuncian la validación de la solicitud de autorización de comercialización de tafasitamab en Europa  2020/05/21 12:23:00 Business Wire
WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte (NASDAQ: INCY) y MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) han anunciado hoy la validación de la solicitud de autorización de comercialización en Europa (MAA en sus siglas en inglés) de tafasitamab, un anticuerpo anti-CD19. La aplicación tiene como objetivo aprobar el uso de tafasitamab en combinación con lenalidomida, seguido de monoterapia con tafasitamab, para el tratamiento de pacientes adultos con linfoma d
   Incyte et MorphoSys annoncent la validation de la demande d'autorisation de mise sur le marché européen du tafasitamab  2020/05/21 10:00:00 Business Wire
WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte (NASDAQ:INCY) et MorphoSys AG (FSE : MOR ; Prime Standard Segment ; MDAX & TecDAX ; NASDAQ:MOR) annoncent aujourd'hui la validation de la demande d'autorisation de mise sur le marché européen (AMM) du tafasitamab, un anticorps anti-CD19. La demande vise à obtenir l'autorisation de commercialiser le tafasitamab en association avec le lénalidomide, puis le tafasitamab en monothérapie, pour le traitement des patients adultes atteints d'un lymphome
   MorphoSys-Aktie im Minus: MorphoSys und Incyte beantragen Zulassung für Tafasitamab  2020/05/21 07:12:00 Finanzen CH
Der Antrag betrifft die Zulassung von Tafasitamab in Kombination mit Lenalidomid zur Behandlung von Patienten mit bestimmten Formen des B-Zell-Lymphoms, eine bösartige Erkrankung des lymphatischen Systems, wie das deutsche Biotechunternehmen MorphoSys mitteilte. Die Validierung…
   Incyte und MorphoSys melden Validierung des europäischen Zulassungsantrags für Tafasitamab  2020/05/21 05:39:00 Business Wire
WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte (NASDAQ:INCY) und MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) gaben heute bekannt, dass der Antrag auf das Inverkehrbringen (MAA) von Tafasitamab, einem Anti-CD19-Antikörper, in Europa für gültig erklärt wurde. Der Antrag betrifft die Zulassung von Tafasitamab in Kombination mit Lenalidomid, gefolgt von einer Tafasitamab-Monotherapie, zur Behandlung von erwachsenen Patienten mit rezidiviertem oder refraktärem diffu
   Resumen: La FDA aprueba Pemazyre™ (pemigatinib) de Incyte como el primer tratamiento específico para adultos con colangiocarcinoma irresecable metastásico o avanzado ya tratado  2020/04/21 00:50:00 Business Wire
WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) ha anunciado hoy que la Administración de Alimentos y Medicamentos (FDA, Food and Drug Administration) ha aprobado Pemazyre™ (pemigatinib), un inhibidor de la quinasa indicado para el tratamiento de adultos con colangiocarcinoma irresecable localmente avanzado o metastásico, previamente tratado, con fusión u otro reordenamiento del receptor del factor de crecimiento de fibroblastos 2 (FGFR2, fibroblast growth factor receptor 2) diagno
   Incyte Gets FDA Nod for Cholangiocarcinoma Drug Pemazyre  2020/04/20 13:57:00 Zacks Investment Research
Incyte (INCY) gets FDA approval for Pemazyre for the treatment of previously-treated, unresectable, locally-advanced or metastatic cholangiocarcinoma.
   Incyte’s Bile Duct Cancer Drug Wins FDA Approval  2020/04/20 11:58:10 Smarter Analyst
Incyte (INCY) has announced that the FDA has approved Pemazyre, a kinase inhibitor for the treatment of adults with unresectable cholangiocarcinoma, a rare cancer … The post Incyte’s Bile Duct Cancer Drug Wins FDA Approval appeared first on Smarter Analyst .
   FDA erteilt Zulassung für Pemazyre™ (Pemigatinib) von Incyte als erste gezielte Therapie für Erwachsene mit vorbehandeltem, inoperablem, lokal fortgeschrittenem oder metastasierendem Cholangiokarzinom  2020/04/19 15:12:00 Business Wire
WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) gab heute bekannt, dass die US-amerikanische Food and Drug Administration (FDA) die Zulassung für Pemazyre™ (Pemigatinib) erteilt hat. Dabei handelt es sich um einen Kinase-Inhibitor, indiziert für die Behandlung von Erwachsenen mit vorbehandeltem, inoperablem, lokal fortgeschrittenem oder metastasierendem Cholangiokarzinom mit Fusion oder sonstiger Umlagerung des Fibroblastenwachstumsfaktorrezeptors 2 (FGFR2), die in einem von der FDA
   Incyte, Novartis Initiate Phase 3 Jakavi Drug Study For Coronavirus Treatment  2020/04/19 13:03:41 Smarter Analyst
Global biotech company Incyte (INCY) announced on Friday that it has initiated a Phase 3 clinical trial in collaboration with Novartis (NVS) to … The post Incyte, Novartis Initiate Phase 3 Jakavi Drug Study For Coronavirus Treatment appeared first on Smarter Analyst .

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 インサイト INCY Incyte Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)